Moreover, various studies have shown that, even in a high androgen milieu, ARCC-4 inhibits prostate tumor cell proliferation and degrades enzalutamide-resistant AR with point mutations, which makes this PROTAC a potential therapeutic option in enzalutamide-resistant patients [113]. This evidence concerns the gene AR and prostate neoplasm.